dan 2163 has been researched along with Schizotypal Personality Disorder in 3 studies
Schizotypal Personality Disorder: A personality disorder in which there are oddities of thought (magical thinking, paranoid ideation, suspiciousness), perception (illusions, depersonalization), speech (digressive, vague, overelaborate), and behavior (inappropriate affect in social interactions, frequently social isolation) that are not severe enough to characterize schizophrenia.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Schmechtig, A | 2 |
Lees, J | 2 |
Grayson, L | 2 |
Craig, KJ | 2 |
Dadhiwala, R | 2 |
Dawson, GR | 2 |
Deakin, JF | 2 |
Dourish, CT | 2 |
Koychev, I | 2 |
McMullen, K | 2 |
Migo, EM | 1 |
Perry, C | 2 |
Wilkinson, L | 2 |
Morris, R | 1 |
Williams, SC | 1 |
Ettinger, U | 2 |
Walters, J | 1 |
Williams, S | 1 |
Barkus, E | 1 |
Ruhrmann, S | 1 |
Bechdolf, A | 1 |
Kühn, KU | 1 |
Wagner, M | 1 |
Schultze-Lutter, F | 1 |
Janssen, B | 1 |
Maurer, K | 1 |
Häfner, H | 1 |
Gaebel, W | 1 |
Möller, HJ | 1 |
Maier, W | 1 |
Klosterkötter, J | 1 |
3 trials available for dan 2163 and Schizotypal Personality Disorder
Article | Year |
---|---|
Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Nic | 2013 |
A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-center double-blind placebo-controlled study.
Topics: Adult; Amisulpride; Analysis of Variance; Biomarkers; Cognition Disorders; Double-Blind Method; Fema | 2012 |
Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Combined Modality Therapy; Drug Administration | 2007 |